Alivus Life Sciences posts steady FY26 growth as margins surge past guidance
The company reported free cash flow of Rs. 2,590 Mn for FY26
The company reported free cash flow of Rs. 2,590 Mn for FY26
Collaboration with Siddhi Diagnostics combines genomics and advanced imaging capabilities to strengthen precision diagnostics in high-growth suburban markets
Union health ministry secretary Punya Salila Srivastava lauds HLL’s six decades of contribution to public healthcare and social development
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
The country’s strength lies not just in technology availability but in adoption behaviour
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Subscribe To Our Newsletter & Stay Updated